decisionhealth Newsletters, Answer Books - 2009 Issue 3 (March)
Anti-Kickback Advisory Opinion Summaries / 2006 OIG Advisory Opinions / Opinion 06-14 - OIG Okays Another PAP For Part D Patients
Subscribe or sign in to view the full article.
Article Overview
This article summarizes a 2006 Office of Inspector General advisory opinion about a drug manufacturer patient assistance program serving Medicare Part D beneficiaries. It explains the general compliance and fraud-and-abuse concerns raised by manufacturer assistance to patients, and it highlights the broad safeguards OIG considered when evaluating the arrangement. The piece is relevant to compliance professionals, reimbursement teams, and healthcare organizations that monitor manufacturer support programs and Medicare Part D interactions.
Why This Topic Matters
It helps readers understand how OIG evaluates manufacturer assistance arrangements that intersect with Medicare Part D and anti-kickback risk.
What You Will Learn
- The general compliance issues raised by manufacturer patient assistance programs for Medicare Part D patients.
- The types of safeguards discussed in an OIG advisory opinion summary.
- How advisory opinions can inform fraud-and-abuse and Medicare Part D policy review.
- The role of patient eligibility, program administration, and recordkeeping in program oversight.
Who Should Read This
- Compliance officers
- Health care attorneys
- Revenue cycle professionals
- Pharmacy organizations
- Payer policy analysts
- Healthcare administrators
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com